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Abstract
Controlling glycemia in diabetes remains key to prevent complications in this condition. However, glucose
levels can undergo large fluctuations secondary to daily activities, consequently creating management diffi-
culties. The current review summarizes the basics of glucose management in diabetes by addressing the main
glycemic parameters. The advantages and limitation of HbA1c, the gold standard measure of glucose control,
are discussed together with the clinical importance of hypoglycemia and glycemic variability. The review
subsequently moves focus to glucose monitoring techniques in diabetes, assessing advantages and limitations.
Monitoring glucose levels is crucial for effective and safe adjustment of hypoglycemic therapy, particularly in
insulin users. Self-monitoring of blood glucose (SMBG), based on capillary glucose testing, remains one of the
most widely used methods to monitor glucose levels, given the relative accuracy, familiarity, and manageable
costs. However, patient inconvenience and the sporadic nature of SMBG limit clinical effectiveness of this
approach. In contrast, continuous glucose monitoring (CGM) provides a more comprehensive picture of glucose
levels, but these systems are expensive and require constant calibration which, together with concerns over
accuracy of earlier devices, restrict CGM use to special groups of patients. The newer flash continuous glucose
monitoring (FCGM) system, which is more affordable than conventional CGM devices and does not require
calibration, offers an alternative glucose monitoring strategy that comprehensively analyzes glucose profile
while sparing patients the inconvenience of capillary glucose testing for therapy adjustment or CGM calibra-
tion. The fast development of new CGM devices will gradually displace SMBG as the main glucose testing
method. Avoiding the inconvenience of SMBG and optimizing glycemia through alternative glucose testing
strategies will help to reduce the risk of complications and improve quality of life in patients with diabetes.
Keywords: Self-monitoring of blood glucose (SMBG), Continuous glucose monitoring (CGM), Flash con-
tinuous glucose monitoring (FCGM), Type 1 diabetes (T1DM), Type 2 diabetes (T2DM), Hypoglycemia,
Glycemic variability.
Introduction
The prevalence of diabetes is on the increase globallyand a multifactorial approach is required to reduce the
risk of complications and consequent morbidity andmortality
in this condition.1–3 Controlling glycemia in diabetes remains
key to prevent microvascular complications and reduce long-
term risk of macrovascular disease.4–6 However, optimizing
glucose levels can be problematic, particularly in patients
with type 1 diabetes (T1DM) or insulin-treated type 2 dia-
betes (T2DM), due to a number of reasons. First, unlike other
risk factors, glucose levels undergo large fluctuations during
the day secondary to daily activities and hypoglycemic
therapies, creating challenges in management. Second, the
safe and effective control of glycemia, particularly in insulin-
treated patients, dictates regular monitoring of glucose levels,
usually performed through self-monitoring of blood glucose
(SMBG). However, SMBG is not always performed fre-
quently enough and can be inconvenient to sustain long term.
Third, one consequence of tight glycemic control is hypo-
glycemia, an unpleasant and potentially dangerous experi-
ence for patients, that can be difficult to predict or even
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capture with the sporadic nature of SMBG. Although inten-
sification of glycemic therapy can precipitate hypoglycemia,
this complication is also seen in those with elevated HbA1c,
and therefore, hypoglycemia is not necessarily a reflection of
tight glucose control. An alternative to SMBG is continuous
glucose monitoring (CGM) that provides a more compre-
hensive picture of glucose changes, but the use of this tech-
nology in diabetes is generally limited at present.
The current review will cover glycemic management in
diabetes by addressing clinically relevant parameters to-
gether with the advantages and drawbacks of current glucose
testing methods. Special emphasis will be placed on the po-
tential clinical benefit of using systems other than SMBG for
measuring glucose in individuals with diabetes.
Glycemic Parameters and Clinical Outcome
Hyperglycemia, hypoglycemia, and glycemic variability
(GV) have been linked to adverse clinical outcomes, which
will be briefly discussed below.
Hyperglycemia
It is well accepted that hyperglycemia in diabetes directly
contributes to short/long-term microvascular complications
and has a long-term role in the development of macrovascular
disease.5,7 Several mechanisms have been proposed for the
adverse vascular effects of hyperglycemia, including increased
oxidative stress and enhanced mitochondrial superoxide pro-
duction,8 as well as endothelial dysfunction leading to the
development of an inflammatory/thrombotic environment.9
The role of improving glycemia in preventing vascular
complications has been extensively studied in various dia-
betes populations. The Diabetes Control and Complications
Trial (DCCT), conducted on 1441 patients with T1DM, has
shown that a reduction in HbA1c by 1.7% decreases micro-
vascular complications over a median follow-up of 6.5
years.4 Interestingly, some of these benefits were observed
early such as nephropathy where albuminuria was reduced
within 1 year of maintaining good glycemic control. At the
end of DCCT, more than 95% of patients agreed to partici-
pate in an extension to the study using an observational design
in the Epidemiology of Diabetes Interventions and Compli-
cations (EDIC). In EDIC, HbA1c levels became similar in
intervention and standard groups, but a reduction in macro-
vascular complications over a follow-up period of 10 years
was evident in those who previously received intensive in-
tervention for glycemia,5 stressing the importance of con-
trolling glucose levels early in the disease process. More
recently, 30-year follow-up data of DCCT have been pub-
lished, which further demonstrate a difference between two
study arms in relation to macrovascular complications.10
The UK Prospective Diabetes Study (UKPDS) random-
ized 4209 newly diagnosed T2DM patients to intensive and
standard glycemic control and included an extension obser-
vational period mimicking the design of DCCT-EDIC. The
findings in UKPDS were largely similar to DCCT-EDIC with
early and late reduction in microvascular and macrovascular
complications, respectively, although this was observed with
a more modest 0.9% difference in HbA1c comparing study
arms.11 Results from DCCT-EDIC and UKPDS led to the
concept of metabolic memory or legacy effect calling for early
control of glycemia to reduce long-term vascular complications.
However, studies on intensive glycemic management in
diabetes patients with established macrovascular disease
have raised concerns. Although a reduction in microvascular
disease was demonstrated with tight glycemic control,12,13
this was associated with increased mortality in the Action to
Control Cardiovascular Risk in Diabetes (ACCORD) study,
involving 10,251 high vascular risk patients.13 It is worth
noting that target HbA1c in the intervention arm was an am-
bitious 6.0% (reaching 6.5% in the study), whereas the stan-
dard arm had a respectable HbA1c of 7.4%. No clear reasons
have been identified for the increased mortality in the inter-
vention arm of the ACCORD trial, although various hypoth-
eses have been put forward, including increased incidence of
severe hypoglycemia.14
A general criticism of glycemic outcome studies is the use
of HbA1c as the main assessor of glycemia, an approach that
has a number of limitations. First, HbA1c does not always
give an accurate measure of average glucose levels. For
example, an HbA1c of 7% (53mmol/mol), indicating good
glycemic control, reflects an average glucose of anything
between 123 and 185mg/dL, a range that becomes even
wider with higher HbA1c of 10% (range 192–282mg/dL);
therefore, HbA1c represents only a rough estimation of aver-
age glucose levels.15 Second, HbA1c does not address hypo-
glycemia or GV, both of which are associated with adverse
clinical outcomes (detailed below). Third, HbA1c can be
misleading in patients with blood abnormalities, including the
common iron deficiency anemia, or the presence of advanced
diabetic complications, such as end-stage renal disease.16–19
Therefore, it is important to understand the limitations of
HbA1c and supplement glycemic assessment by glucose
checks, a view supported by the recent ADA recommenda-
tion.20 Figure 1 summarizes the advantages and limitations of
HbA1c as a measure of glycemia.
Hypoglycemia
Hypoglycemia is increasingly seen in diabetes given the
ever tighter glycemic targets and this complication of therapy
can have detrimental effects through a number of mecha-
nisms, including cardiac dysrhythmias, increased produc-
tion of vascular inflammatory molecules, and an enhanced
thrombotic environment (reviewed in Frier et al.21 and King
and Ajjan22). Therefore, it is not surprising that a number of
studies have shown associations between hypoglycemia and
high mortality in patients with both T1DM and T2DM.23–29
Furthermore, accumulating evidence suggests that hypogly-
cemia is more frequent than initially envisaged,30,31 even in
those classified as having ‘‘preserved hypoglycemic aware-
ness’’; therefore, the size of problemmay be even bigger than
previously projected. HbA1c fails to address hypoglycemia
and therefore frequent SMBG, which is impractical, or CGM,
which can be costly, is required to accurately identify periods
of hypoglycemia. The advent of new glucose monitoring
devices that are affordable, convenient, and accurate will
help to further address the role of hypoglycemia in adverse
clinical outcomes (discussed below).
Glycemic variability
Emerging evidence suggests that GV, both medium and
short term, contributes to adverse clinical outcome in dia-
betes. A recent meta-analysis assessing medium-term GV,
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measured as fluctuation in HbA1c, has shown associations
with microvascular and macrovascular complications in
T1DM and T2DM as well as mortality in T2DM.32 Fluc-
tuation in glucose levels has also demonstrated associations
with increased mortality and longer hospital stay, which was
independent of HbA1c levels.33
Proposed mechanisms for the association between GV and
adverse vascular outcomes include increased oxidative stress
and enhanced expression of proteins involved in vascular
pathology.34 This perhaps explains the association between
GV and plaque characteristics as well as atherosclerotic cap
thickness in 70 patients with established coronary artery
disease.35 Moreover, GV may directly predispose to myo-
cardial infarction through the documented association with
coronary plaque instability as shown in 76 individuals with
acute coronary syndrome and T2DM.36
While GV is potentially an important glycemic parameter,
we should be cautious in our conclusions as current evidence
linking GVwith adverse clinical outcomes is relatively weak.
Studies have mainly relied on SMBG or HbA1c measure-
ments for estimation of GV and neither gives a full glycemic
picture. Moreover, there is no standardized definition for GV
at present as a large number of markers have been used
without clear indication as to which one is the most relevant
clinically.37 Also, the magnitude of GV is dependent on av-
erage glucose levels, and therefore, it can be argued that
correction for HbA1c (or mean glucose) is required when
assessing variability, which further complicates matters.38
Finally, the association between GV and low glucose levels,
including nocturnal hypoglycemia,39–41 raises the possibility
that GV is not an independent predictor of adverse clinical
outcome. Therefore, further longitudinal glycemic studies
evaluating the relationship between a standardized measure
of GV and clinical outcome are needed.
The Ideal Glycemic Marker
HbA1c has been used for decades as the main glycemic
marker, which is understandable given the ease of testing and
the documented association between HbA1c and complica-
tions. However, HbA1c is one glycemic marker that displays
only an approximate measure of glucose levels and fails to
address other parameters such as hypoglycemia andGV, both of
which may influence clinical outcome. Therefore, for a com-
prehensive assessment of glycemia, a combination of glycemic
parameters is required that includes hyperglycemia (assessed as
HbA1c as well as glucose levels), hypoglycemia, and GV,
which led to the concept of ‘‘The Triangle of Diabetes Care.’’42
Glycemic assessment should perhaps follow this triple ap-
proach, although the definition of GV is in need of refinement.
It should be noted that these glycemic parameters are not
necessarily independent. For example, GV increases in in-
dividuals with repeated hypoglycemia, whereas large fluc-
tuation in glucose levels can also increase HbA1c.
Glucose Testing Methods
Checking glucose levels becomes important when treating
with oral agents that cause hypoglycemia, such as sulfonyl-
ureas, and a necessity in insulin-treated individuals. Glucose
testing has been performed using three methods: SMBG,
CGM, and, more recently, flash continuous glucose moni-
toring (FCGM).
Self-monitoring of blood glucose
This is the most widely used glucose testing method and
generally enjoys good accuracy but is not devoid of drawbacks.
SMBG is inconvenient to patients as testing can be painful,
many describe it as antisocial, and is affected by daily life
activities, which can pose a problem, particularly in younger
patients. Also, SMBG misreporting remains an issue,43 which
may have serious clinical implications. Importantly, frequent
testing is required to effectively alter management and achieve
good glycemic control. In support of this, an analysis of 20,555
patients with T1DM has shown an inverse correlation between
frequency of glucose testing and HbA1c levels. T1DM indi-
viduals testing three to four times/day had an HbA1c of 8.6%,
dropping to 7.6% in individuals performing ‡10 tests/day,44
with similar findings documented in patients with T2DM.45
FIG. 1. Advantages and limitations of HbA1c. The most widely used measure of glycemia, HbA1c, is easy to measure and
has a clear role in optimizing therapy. However, HbA1c has a number of limitations that should be taken into account in
clinical practice. GV, glycemic variability; Hb, hemoglobin; RF, renal failure.
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This indicates that frequent glucose testing is required to im-
prove glycemic control, which can be difficult to maintain long
term. Finally, the quality of the glucose testing strips can be
variable and some versions do not necessarily provide high
accuracy, emphasizing the importance of ongoing quality
control studies.46
Continuous glucose monitoring
CGM devices, recording interstitial glucose every 5min,
have the advantage of giving a more comprehensive picture
of glycemia by providing a large number of glucose readings.
Sensor life is limited to 1 week at best, although this is ex-
tended to 2 weeks with FCGM that offers an alternative form
of CGM (detailed below). A new generation of implantable
sensors further extends sensor life to 6 months,47 but the large
interindividual variability observed (100%, 82%, and 40% of
sensors were functional at 45, 90 and 180 days, respectively)
and the limited accuracy at lower glucose levels indicate that
further refinement is needed before implantable sensors are
available to use in clinical practice.
CGM has been used retrospectively and in real time with
the latter having the advantage of responding quickly to un-
wanted changes in glucose levels. CGM has also been used
linked to insulin pumps allowing the development of sensor-
augmented pumps that suspend insulin infusion when hypo-
glycemia is detected or predicted,48,49 with more sophisti-
cated systems even adjusting for hyperglycemia.50
In general, CGM studies have shown an improvement in
glycemia, measured as HbA1c, and/or reduction in hypo-
glycemia, rendering them cost-effective in some diabetes
populations despite the high outlay compared with SMBG
(reviewed in Vigersky and Rodbard51,52). However, CGM
is still not widely used, secondary to inertia of physicians,
concerns over accuracy, and the general high costs, as well as
patient-related factors, including the need for constant cali-
bration and difficulties encountered in data interpretation.
What are the key glycemic measures generated by
CGM? Interpreting CGM data can pose a challenge to
patients and healthcare professionals (HCP) alike. Therefore,
attempts have been made to standardize CGM glycemic
measures. A recent consensus conference suggested that rel-
evant CGMdata should include current glucose levels, glucose
trend arrows, default alert for hypoglycemia set at <70mg/dL,
and the inclusion of a standardized report that includes various
glucose metrics such as time in range, GV, and patterns of
hypoglycemia and hyperglycemia.53 However, a clear process
for analyzing long-term glucose data is still lacking and this is
currently left at the discretion of the HCP. Ambulatory glucose
profile (AGP), generated by CGM, has been proposed as a
good platform to standardize interpreting glucose data and
draw up effective management decisions.54
Retrospective or real-time CGM? Retrospective CGM,
also referred to as professional CGM, is usually used inter-
mittently and mainly for diagnostic purposes with the patient
blinded to glucose data. In contrast, real-time CGM, usually
used longer term, enables patients to see glucose readings and
make management changes as appropriate.55 The latter is
equipped with an alarm system to warn of hypoglycemia that
can be particularly helpful in those with hypoglycemic un-
awareness. Using retrospective or real-time CGM depends
on the type of patients and the reasons for requesting CGM.
Younger patients, majority of whom have T1DM, are gen-
erally more comfortable at making changes to their treatment
and usually benefit from real-time CGM. Some of the older
patients with insulin-treated T2DM are less likely to make
changes to their treatment without input from the HCP, and
therefore, retrospective CGM may be more appropriate, al-
though this cannot be generalized. However, this view is
challenged by others who advocate replacing blinded with
real-time CGM for both T1DM and T2DM patients.56
Is CGM appropriate for all patients with diabetes? The
benefits of CGM in children and younger adults with T1DM
are beyond doubt with a number of studies showing im-
provement in glycemic control and reduction in hypoglyce-
mia. The landmark Juvenile Diabetes Research Foundation
( JDRF) trials, using the three main CGM devices (DexCom,
Medtronic, and FreeStyle Navigator) have shown that CGM
improves HbA1c by 0.5%–0.8% without an increase in
hypoglycemia in 322 individuals with T1DM and starting
HbA1c >7.0%.57 A secondary study evaluated 129 T1DM
patients with HbA1c <7.0% and demonstrated reduction in
hypoglycemia by 30%–50% using real-time CGM, indicating
a benefit even in those who are labeled as having good glu-
cose control. A meta-analysis of 10 studies comparing real-
time CGM with SMBG in T1DM showed a 0.26% reduction
in HbA1c without an increase in hypoglycemia further sup-
porting the use of CGM in this population.58 It should be
noted that these glycemic benefits were evident with early
CGM devices, which had inferior accuracy compared with
current sensors. Therefore, more studies are required with the
new sensors and some are already underway. One recent
multicenter CGM study, including a modest number of 25
patients with T1DM and using AGP for glycemic assessment,
has shown a marginal reduction in HbA1c of 0.3% (P= 0.05)
comparing baseline with 3 months of sensor use, associated
with a significant reduction in hypoglycemia from 1.4 – 1.7
to 0.8 – 0.8 h/day.31 One advantage of this work is a real-life
study design where treatment changes were left at the dis-
cretion of the HCP, but larger trials are needed before con-
crete conclusions can be drawn. Two more recent high-
quality multicenter studies have been conducted to further
investigate the role of CGM in T1DM patients treated with
multiple daily insulin (MDI) injections.59,60 The first is the
DIAMOND trial, a randomized multicenter study conducted
in the United States involving 24 endocrine centers and 158
patients with T1DM. Inclusion criteria included age >25
years, HbA1c between 7.5% and 10.0%, and treatment with
MDI injections. Randomization took a 2:1 assignment to
intervention (n = 105), using Dexcom Platinum 4 with an
enhanced algorithm (software 505) or control group (n = 53)
relying on SMBG for measurement of glucose levels (at least
four times/day). The intervention group was instructed to test
blood glucose twice/day (to calibrate the device) as well as
before insulin dosing. A total of 155 individuals completed
the study (102 and 53 in the intervention and control groups,
respectively), indicating excellent retention rate. HbA1c at
24 weeks, the primary endpoint, was 0.6% lower in inter-
vention compared with the control group. Moreover, this was
associated with a significant reduction in hypoglycemia in the
intervention compared with the standard arm of the study,
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indicating that CGM reduces both hyper- and hypoglycemia
in T1DM onMDI therapy. However, important limitations of
the study are exclusion of individuals younger than 25 years
of age and those with HbA1c >10%, making general appli-
cability of the results to all MDI-treated T1DM patients un-
certain. Furthermore, individuals in the intervention arm
continued to perform SMBG to calibrate the device and to
test before meals, practically making the intervention arm
a combination of SMBG and CGM. Finally, it is unclear
whether these glycemic improvements are sustained and
observational studies using real-life setting will help to
clarify the effects of this glucose monitoring strategy on long-
term glycemic control. The second study is the GOLD trial,
conducted in Sweden on MDI-treated T1DM patients. A total
of 161 patients were recruited with inadequate glycemic
control, defined asHbA1c >7.5%, andwithout having an upper
limit. Patients were randomized to Dexcom Platinum G4 or
standard capillary glucose monitoring. This was an ambitious
crossover trial with data analyzed at 26 and 69 weeks, which
included 17 weeks of wash-out period. A total of 142 patients
completed the trial, demonstrating a lower retention rate
compared with DIAMOND. There was 0.4% improvement in
HbA1c in those using CGM compared with SMBG, associated
with higher treatment satisfaction and lower fear of hypogly-
cemia, indicating improvement in quality-of-life measures in
these patients. Of note, the crossover design showed that CGM
not only improves glycemia at both intervention periods but
discontinuation of this glycemic monitoring strategy also re-
sults in worsening of glucose control.
Taken together, randomized controlled trials (RCTs) in
T1DM patients show that CGM improves glycemic control
regardless whether patients are treated with an insulin pump
or receivingMDI therapy. Naturally, there is always the issue
of selection bias with CGM studies, and therefore, real-life
clinical data are required to further understand the sub-
group(s) of patients who would benefit the most from this
glucose monitoring strategy. Information overload has been
criticized as a drawback of CGM in T1DM, but studies have
shown no increase in psychosocial stress, making this glu-
cose testing method both convenient and effective.61,62
In contrast to T1DM, only limited studies, frequently with
a retrospective design and involving a low number of pa-
tients, investigated the use of CGM in T2DM. Findings
ranged from no effect on glycemia to significant reduction in
HbA1c and/or hypoglycemia (summarized in Vigersky and
Shrivastav55). One additional multicenter study conducted
over 3 months investigated the role of CGM/AGP in 28
T2DMpatients onMDI regimen and has shown a reduction in
HbA1c by 0.9% comparing baseline with study end without
an increase in hypoglycemia,31 suggesting this group of pa-
tients may benefit from CGM.
Clearly, more CGM studies are required in T2DM, partic-
ularly in high-risk groups such as older individuals, those with
a history of severe hypoglycemia, advanced renal disease, or
vascular complications.53 Pregnant women with diabetes are
also likely to benefit from CGM and although some work
supports this view,63 more studies in this area are warranted.
Flash Continuous Glucose Monitoring
The FreeStyle Libre is a relatively new glucose monitoring
system that resembles established CGM devices as it mea-
sures interstitial glucose every minute and records readings
every 15 mins.64 FCGM has a number of advantages over
conventional CGM, including factory calibration, thus of-
fering a genuine break from capillary glucose testing, long
sensor life of 2 weeks, and relatively low costs. There are two
forms of the device, FreeStyle Libre and Libre Pro for real-
time and retrospective glucose data analysis, respectively
(https://freestylediabetes.co.uk and //www.freestylelibrepro.
us). The Libre device is composed of a glucose sensor that
stores 8 h of data and transfers this to the reader wirelessly
during glucose checks by the patient. Therefore, a full 24 h
glucose profile is provided by scanning three times/day, but
in practice, patients end up scanning 8–14 times/day.65,66 In
contrast, Libre Pro stores 14 days of data and therefore all
glycemic measures are downloaded just once.
FreeStyle Libre presents glucose measures as numbers and
trend arrows with longer term data presented as AGP and
time spent in euglycemia, hypoglycemia, and hyperglycemia
allowing for quick data interpretation. A systematic approach
to AGP, modified according to local need, facilitates patient
education on glucose patterns and provides a useful tool to
safely and effectively alter hypoglycemic therapy.67 More-
over, the glucose reader can act as a capillary glucose and
ketone monitor further increasing convenience and ensuring
that patients do not need to carry two devices. Accuracy of
FreeStyle Libre is similar to conventional CGM devices with
a mean absolute relative difference (MARD) of 11.4%, but
the system fails to provide an alarm to warn of hypoglycemia
and current versions do not have the facilities to directly
connect to insulin pumps.
Recent multicenter trials have shown that FreeStyle Libre
use is associated with improved glycemic parameters in
insulin-treated patients with diabetes. The IMPACT trial,
involving 23 European sites and 241 T1DM patients with
good glycemic control (HbA1c 6.7%) and no history of hy-
poglycemic unawareness, randomized 120 patients to Free-
Style Libre and 121 to SMBG. The study met the primary
endpoint showing 38% reduction in time spent in hypogly-
cemia at 6 months with FreeStyle Libre while maintaining
HbA1c (hypoglycemia reduction by 1.39 and 0.14 h/day in
intervention and control arms, respectively; P < 0.001).65
Interestingly, the reduction in hypoglycemia was evident
within the first month of starting the trial and was sustained
throughout. The REPLACE multicenter study, conducted in
26 European centers, investigated the use of FreeStyle Libre
in 224 patients with T2DM on multiple daily injections of
insulin. Individuals were randomized to intervention with
FreeStyle Libre, while the control group continued to use
SMBG (2:1 randomization). The primary endpoint was dif-
ference in HbA1c between study arms at 6 months. Although
no significant difference in HbA1c was shown, individuals
younger than 65 years demonstrated a reduction in HbA1c by
0.5% in the intervention arm compared with 0.2% in con-
trols (P < 0.05).66 Moreover, hypoglycemia was reduced by
43% in intervention compared with control arm (P< 0.001),
associated with improvement in quality-of-life measures
(P< 0.001). The reduction of hypoglycemia in both IMPACT
and REPLACE, including nocturnal hypoglycemia, occurred
despite the absence of an alarm in the FreeStyle Libre system.
In summary, CGM and FCGM use improves HbA1c and/
or reduces hypoglycemia, although more studies in T2DM
patients are needed to identify subgroups that would benefit
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the most from non-SMBG methods for glucose testing. The
advantages and limitations of glucose testing methods are
summarized in Figure 2.
Accuracy of CGM Sensors in Clinical Practice
Accuracy of earlier sensors such as GlucoWatch G2 was
disappointing with a MARD of 22%. However, this has
significantly improved over the past decade with MARD
gradually dropping to 13.8% with Enlite, 13.0% with Dex-
com G4 platinum, 12.8% with FreeStyle Navigator, and an
impressive 9.0%with DexcomG4 platinum equipped with an
advanced software.68 Although of great clinical interest, head
to head studies comparing different sensors are relatively
scarce. In 24 patients with T1DM, Dexcom showed superior
accuracy to Enlite sensor (Medtronic), demonstrating an
MARD – SD of 12.2% – 12.0% and 19.9% – 20.5%, respec-
tively (P < 0.001). Accuracy suffered in the hypoglycemic
range, but a difference between the two sensors was still
evident (21.2% – 21.8% and 36.2% – 42.6%, respectively;
P < 0.001).69 Funding of the work by Dexcom and the direct
supply of the sensors by the company were criticized, but
another study, independent of either of the two companies,
showed similar results with greater accuracy of Dexcom
compared with Enlite in 38 subjects with T1DM (MARD of
13.9% and 17.8%, respectively; P < 0.001).70
Despite not needing calibration, the new FreeStyle Libre
shows good accuracy with a MARD of 11.4%, which is not
affected by body mass index, age, type of diabetes, or treat-
ment with insulin.64 In a head to head comparison of Libre
with Dexcom G4 in patients with T1DM, a good agreement
was detected with a MARD in euglycemic, hyperglycemic,
and hypoglycemic range of 15.8%, 13.4%, and 18.7%.71
Subtle differences were detected such as lower glucose
reading with Libre overnight, but this was minor and did not
have management implications.71 Compared with SMBG,
both sensors showed a MARD <15% but it is worth stressing
that Dexcom users had to calibrate their device twice daily,
whereas those on Libre did not require calibration.
A key issue remains in relation to nonadjunctive use of
CGM to make treatment decisions. The reluctance to rely
only on CGM data is related to sensor delay and concerns
over accuracy, particularly in certain situations, such as in-
correct calibration, compression of sensor site, and sensor
interfering substances (except for the Libre sensor) such
as acetaminophen. One of the proposed MARD safety
thresholds of 10% appears to be the current cutoff for non-
adjunctive CGM use, which is met by Dexcom G4 platinum
coupled with 505 software.72 Indeed, a recent study using this
device, REPLACE-BG, randomized 226 T1DM patients
from 14 centers to CGM-only group (n = 149) or control
group (CGM+SMBG, n = 77). Patients were adults, on in-
sulin pumps, had HbA1c <9.0% (<75mmol/mol) with almost
half being CGM users before the study. Mean time in eu-
glycemia, defined as glucose between 70 and 180mg/dL,
remained constant in both groups at 26 weeks compared with
baseline, indicating that CGM can be used solely to monitor
glycemia and adjust therapy. It should be noted, however,
that SMBG was still needed in the CGM-only group at a
mean of 2.8 tests/day (mainly to calibrate the device) as
opposed to 5.4 tests conducted in the CGM+SMBG group.73
Recommendations for CGM Use in Clinical Practice
Various guidelines have been developed for CGM use in
patients with diabetes. However, given the general paucity of
data, these guidelines have generally adapted a pragmatic
approach by trying to address subgroups of patients who
would most benefit from this glycemic monitoring strategy.
The National Institute for Health and Care Excellence re-
commendedCGMuse for thosewhoseHbA1c is poor despite at
least 10 SMBG tests/day.74 Moreover, patients with more than
one episode of severe hypoglycemia/year, complete unaware-
ness of hypoglycemia, frequent asymptomatic hypoglycemia
FIG. 2. Advantages and limitations of SMBG, CGM, and FCGM. SMBG is inconvenient and fails to provide a complete
set of glucose data. In contrast, both CGM and FCGM provide a comprehensive picture of glucose levels with the former
having an alarm function and the ability to link with IP. CGM devices require constant calibration and current systems are
expensive, whereas FCGM does not require calibration, enjoys long sensor life, and is relatively affordable. CGM, con-
tinuous glucose monitoring; FCGM, flash continuous glucose monitoring; IP, insulin pumps; SMBG, self-monitoring of
blood glucose.
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compromising daily activities, and extreme fear of hypoglyce-
mia were also recommended as candidates for CGM. Long-
term CGM use, however, required demonstrating clinical ben-
efit, including a significant drop in HbA1c.
The recent endocrine society clinical practice guidelines
have generally simplified the criteria for CGM use.75 Of note,
panel members commissioned a systematic review and meta-
analysis of RCTs to acquire a solid evidence-based platform
for their recommendations. Pooled data from 11 RCTs on the
use of real-time CGM in T1DM demonstrated that this glu-
cose monitoring strategy alters HbA1c (95% CI) by -0.28%
(-0.47, -0.09), which is primarily seen in patients older
than 15 years. Therefore, use of real-time CGM was re-
commended for T1DM patients who have HbA1c above
targets and who are willing, as well as able, to use the device
on almost a daily basis. Also, it was highlighted that CGM
reduces the risk of hypoglycemia, particularly with lower
HbA1c levels. Intermittent CGM was suggested for insulin-
treated T2DM patients, although it was acknowledged that
the evidence in this group of patients is both weak and in-
complete. The guidelines stressed the importance of patient
education and support during periods of CGM use. Sensor-
augmented insulin pump therapy as an effective tool to re-
duce nocturnal hypoglycemia was also recommended.
In summary, current evidence indicates that CGM use,
with appropriate education and support, is advised for T1DM
patients not achieving HbA1c targets with SMBG. Also,
CGM is justified in T1DM individuals in whom hypoglyce-
mia represents a significant clinical problem. CGM can also
be used in T2DM patients with suboptimal HbA1c but only
intermittently and long-term use is not advised. Finally, CGM
is likely to be useful in pregnant women with diabetes,63
although more studies are required in this group of patients.
FCGM is noted by its absence from current guidelines,
which is not surprising given this is a new device that requires
further assessment before robust recommendations can be
made. However, limited evidence from two RCTs suggests a
benefit in both T1DM and T2DM patients on multiple daily
injections with insulin.65,66 The rapid increase in FCGM users
will provide further crucial data on the role of this glucose
monitoring strategy in optimizing glycemic control in diabe-
tes. It should be remembered that FCGM is a calibration-free
device with longer sensor life but lacks alarm function and is
not currently linked to an insulin pump. Therefore, clinical
indications for the two glucose monitoring strategies can be
different in some individuals and further studies are required to
characterize these subgroups.
Conclusions and the Way Forward
Although HbA1c has been a useful clinical marker of
glycemia, it reflects an approximate measure of glucose
levels, displays large interindividual variability, and only
provides a unidimensional analysis as it fails to address hy-
poglycemia and GV. Glucose testing by SMBG has been a
cornerstone in glycemic management, but it is inconvenient
to patients, particularly as a large number of daily tests are
required for safe and effective changes in therapy. CGM
certainly provides a more comprehensive assessment of
glycemia, but uptake has been limited due to the need for
constant calibration, high cost, and concerns over accuracy,
in addition to difficulties encountered with data interpreta-
tion. However, with the advent of new and affordable glucose
monitoring devices, such as FCGM, the widespread use of
non-SMBG methods for glucose testing is becoming a pos-
sibility. Development of an algorithm for data analysis will
further help in interpreting glucose data and make CGM/
FCGM more user friendly for both patients and HCP.
The type of diabetes patient likely to benefit from CGM/
FCGM has not been fully characterized with current evi-
dence, suggesting that both of these systems are beneficial in
individuals with T1DM by maintaining good glucose control
while reducing the risks of hypoglycemia. CGM is also useful
in individuals with a history of severe hypoglycemia or hy-
poglycemic unawareness and accumulating evidence sug-
gests that some form of CGM is warranted in those with
suspected hypoglycemia, particularly nocturnal.
Other groups that may benefit from CGM/FCGM include
insulin-treated patients with T2DM, although studies in this
group of patients remain surprisingly scarce. The heteroge-
neity observed in T2DM calls for additional work to further
identify subgroups that would particularly benefit from this
glucose monitoring strategy. For example, non-SGBG-based
glucose testing is likely to be useful in individuals with
Table 1. Clinical Use of Continuous Glucose Monitoring and Flash Continuous Glucose Monitoring
CGM FCGM
HbA1c Reduction in T1DM57–60
Reduction/no change in insulin-treated
T2DM (limited studies in this group)31,55
Reduction in insulin-treated T2DM,
younger than 65 years
(based on a single study)66
Hypoglycemia Reduction in T1DM31,57–60
Reduction in insulin-treated T2DM31,55
Reduction in T1DM and well-controlled HbA1c65
Reduction in insulin-treated T2DM66
Diabetes groups
likely to
benefit53,63,65,66,72–75
T1DM (willing to test glucose to calibrate)
Some insulin-treated T2DM
(to be fully characterized)
Individuals at risk of hypoglycemia
or those with hypoglycemic unawareness
Pregnant women with diabetes
Majority of T1DM (more studies are required)
Some insulin-treated T2DM (to be fully
characterized; those aged <65 years may
constitute one group)
Individuals at risk of hypoglycemia
Pregnant women with diabetes
Self-monitoring of blood glucose is currently the most widely used method for measuring glucose levels with CGM reserved for more
complicated patients with T1DM and T2DM. FCGM, which is similar to conventional CGM, is a relatively new form of glucose testing
with studies demonstrating benefits in both T1DM and T2DM.
CGM, continuous glucose monitoring; FCGM, flash continuous glucose monitoring; T1DM, type 1 diabetes; T2DM, type 2 diabetes.
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diabetes following a major vascular event, such as myocar-
dial infarction or stroke, those with advanced renal disease or
blood disorders where HbA1c is less reliable as a marker of
glycemia.
In addition to RCTs, observational studies using real-life
CGM/FCGM data are required to fully assess the impact of
these glucose monitoring strategies on glycemic measures
and clinical outcomes in patients with diabetes. Main clinical
benefits of CGM/FCGM are summarized in Table 1.
Widespread use of non-SMBG testing and the develop-
ment of glycemic assessment protocols will familiarize both
patients and HCP with alternative glucose testing methods,
allowing for maximal clinical impact. Moreover, the in-
crease in prevalence of non-SMBG devices will help com-
panies reduce the price and further increase investment into
improving accuracy and durability of sensors.
The ‘‘glycemic future’’ of patients with diabetes looks
promising, which in turn will help to reduce complications,
consequently improving quality of life and decreasing mor-
tality in this high-risk population.
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